The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth

被引:2
|
作者
Qian, Jing [1 ,8 ]
Ma, Yanxia [1 ,7 ]
Tahaney, William M. [1 ,2 ,6 ]
Moyer, Cassandra L. [1 ]
Lanier, Amanda [1 ]
Hill, Jamal [1 ]
Coleman, Darian [1 ]
Koupaei, Negar [1 ,4 ]
Hilsenbeck, Susan G. [3 ]
Savage, Michelle I. [1 ]
Page, Brent D. G. [5 ]
Mazumdar, Abhijit [1 ]
Brown, Powel H. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dan L Duncan Canc Ctr, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX USA
[5] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[6] Monte Rosa Therapeut, Boston, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX USA
[8] Univ Texas MD Anderson Canc Ctr, UTHealth Houston Grad Sch Biomed Sci, Houston, TX USA
关键词
Phosphatase; Triple-negative breast cancer; Oxidative stress; EXPRESSION;
D O I
10.1186/s13058-024-01778-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe most aggressive form of breast cancer is triple-negative breast cancer (TNBC), which lacks expression of the estrogen receptor (ER) and progesterone receptor (PR), and does not have overexpression of the human epidermal growth factor receptor 2 (HER2). Treatment options for women with TNBC tumors are limited, unlike those with ER-positive tumors that can be treated with hormone therapy, or those with HER2-positive tumors that can be treated with anti-HER2 therapy. Therefore, we have sought to identify novel targeted therapies for TNBC. In this study, we investigated the potential of a novel phosphatase, NUDT5, as a potential therapeutic target for TNBC.MethodsThe mRNA expression levels of NUDT5 in breast cancers were investigated using TCGA and METABRIC (Curtis) datasets. NUDT5 ablation was achieved through siRNA targeting and NUDT5 inhibition with the small molecule inhibitor TH5427. Xenograft TNBC animal models were employed to assess the effect of NUDT5 inhibition on in vivo tumor growth. Proliferation, death, and DNA replication assays were conducted to investigate the cellular biological effects of NUDT5 loss or inhibition. The accumulation of 8-oxo-guanine (8-oxoG) and the induction of gamma H2AX after NUDT5 loss was determined by immunofluorescence staining. The impact of NUDT5 loss on replication fork was assessed by measuring DNA fiber length.ResultsIn this study, we demonstrated the significant role of an overexpressed phosphatase, NUDT5, in regulating oxidative DNA damage in TNBCs. Our findings indicate that loss of NUDT5 results in suppressed growth of TNBC both in vitro and in vivo. This growth inhibition is not attributed to cell death, but rather to the suppression of proliferation. The loss or inhibition of NUDT5 led to an increase in the oxidative DNA lesion 8-oxoG, and triggered the DNA damage response in the nucleus. The interference with DNA replication ultimately inhibited proliferation.ConclusionsNUDT5 plays a crucial role in preventing oxidative DNA damage in TNBC cells. The loss or inhibition of NUDT5 significantly suppresses the growth of TNBCs. These biological and mechanistic studies provide the groundwork for future research and the potential development of NUDT5 inhibitors as a promising therapeutic approach for TNBC patients.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Novel prognostic markers for patients with triple-negative breast cancer
    Zhou, Ling
    Li, Ke
    Luo, Yanli
    Tian, Ling
    Wang, Min
    Li, Chuanyuan
    Huang, Qian
    HUMAN PATHOLOGY, 2013, 44 (10) : 2180 - 2187
  • [2] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
    Boscolo Bielo, Luca
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 789 - 801
  • [3] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [4] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) : 1938 - 1948
  • [5] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [6] Emerging Novel Therapeutics in Triple-Negative Breast Cancer
    Lyons, Tomas G.
    Traina, Tiffany A.
    BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 377 - 399
  • [7] Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer
    Zhang, Qian-Qian
    Chen, Jian
    Zhou, Da-Lei
    Duan, You-Fa
    Qi, Cui-Ling
    Li, Jiang-Chao
    He, Xiao-Dong
    Zhang, Min
    Yang, Yong-Xia
    Wang, Lijing
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2017, 13 (04): : 471 - 479
  • [8] Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer
    Rhodes, Lyndsay V.
    Tilghman, Syreeta L.
    Boue, Stephen M.
    Wang, Shuchun
    Khalili, Hafez
    Muir, Shannon E.
    Bratton, Melyssa R.
    Zhang, Qiang
    Wang, Guangdi
    Burow, Matthew E.
    Collins-Burow, Bridgette M.
    ONCOLOGY LETTERS, 2012, 3 (01) : 163 - 171
  • [9] Metabolic reprogramming in triple-negative breast cancer
    Wang, Zhanyu
    Jiang, Qianjin
    Dong, Chenfang
    CANCER BIOLOGY & MEDICINE, 2020, 17 (01) : 44 - 59
  • [10] Atezolizumab for the treatment of triple-negative breast cancer
    Heimes, Anne-Sophie
    Schmidt, Marcus
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5